SJS Investment Consulting
MLTX icon

SJS Investment Consulting’s MoonLake Immunotherapeutics MLTX Stock Holding History

SJS Investment Consulting’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.68K Buy
144
+90
+167% +$1.47K ﹤0.01% 2279
2026
Q2 		$1.05K Buy
+54
New +$979 ﹤0.01% 2014

Other funds holding MLTX

Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Congress Asset Management
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Zurich Cantonal Bank
Zurich Cantonal Bank Zurich, Switzerland $53.5B AUM 32.01% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

SJS Investment Consulting's MLTX Position: Q3 2026 in Review

SJS Investment Consulting increased its MoonLake Immunotherapeutics (MLTX) stake by 167% in Q3 2026, buying an estimated $1.47K and bringing the position to 144 shares worth $1.68K. The position accounts for ﹤0.01% of the portfolio, ranked #2279.

SJS Investment Consulting first reported a position in MLTX in Q2 2026 and has held it in 2 quarters since. 57 funds tracked by Wall St. Rank hold MLTX as of Q3 2026.

  • SJS Investment Consulting held 144 shares of MoonLake Immunotherapeutics worth $1.68K as of Q3 2026.
  • SJS Investment Consulting bought 90 MoonLake Immunotherapeutics shares in Q3 2026, an estimated $1.47K.
  • MoonLake Immunotherapeutics made up ﹤0.01% of SJS Investment Consulting's portfolio in Q3 2026, its #2279 holding.
  • SJS Investment Consulting first reported a position in MoonLake Immunotherapeutics in Q2 2026 and has held it in 2 quarters since.
  • 57 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2026.

Based on SJS Investment Consulting's 13F filing for Q3 2026, filed 26 Oct 2026.